Advocating for Impact: 340B State Laws Win Big in Court

In November 2021, Arkansas enacted a law, known as Act 1103, that prohibited drugmakers from placing restrictions on 340B contract pharmacies and child sites. The Pharmaceutical Research and Manufacturers of America (PhRMA) immediately filed suit to block implementation of Act 1103, delaying enforcement of the law for nearly 2 years. However, on March 12, 2024, the U.S. Court of Appeals for the Eighth Circuit rejected PhRMA’s arguments and ruled Act 1103 is valid and enforceable. In the podcast, we talk about the implications of the ruling for the broader 340B program and covered entities nationwide. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.